Skip to content

LAMP-COVID: Locating Amyloid-containing Microclots with total-body PET in post-COVID syndrome

Status
Not yet recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522348-42-00
Enrollment
65
Registered
2026-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-COVID syndrome (long COVID)

Brief summary

Quantitative measures of [18F]Flutemetamol binding throughout the body of participants, expressed in parameters such as volume of distribution (VT) or non displaceable binding potential (BPND) (depending on the most suitable kinetic model per region or tissue of interest (ROI)).

Detailed description

Amyloid-containing microclot load (size and quantity) in blood., Questionnaire scores on presence and severity of (post-COVID) symptoms, MRI-derived parameters on brain structure and function.

Interventions

Sponsors

Amsterdam UMC Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Quantitative measures of [18F]Flutemetamol binding throughout the body of participants, expressed in parameters such as volume of distribution (VT) or non displaceable binding potential (BPND) (depending on the most suitable kinetic model per region or tissue of interest (ROI)).

Secondary

MeasureTime frame
Amyloid-containing microclot load (size and quantity) in blood., Questionnaire scores on presence and severity of (post-COVID) symptoms, MRI-derived parameters on brain structure and function.

Outcome results

None listed

Source: EU CTIS · Data processed: May 8, 2026